Institution
Cognition Therapeutics (United States)
UScompany
Recent research
- BiologyOpen access
Crystal Structureof the Sigma-2 Receptor Complexedwith Investigational Drug Zervimesine (CT1812)
Abstract The investigational drug zervimesine (CT1812) is an allosteric small molecule modulator of the sigma-2 receptor (S2R), known as transmembrane protein 97 (TMEM97), currently in clinical development for Alzheimer’s disease and dementia with Lewy bodies. In Phase 2 trials,...